日期: 2026 年 1 月 12 日

SAN DIEGO, Jan 13, 2026 - (ACN Newswire via SeaPRwire.com) - Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028.GA-ASI and NSPA signed a contract to purchase eight MQ-9B SeaGuardians for Germany on January 12. From left to right: Allan McLeod, NSPA, Chris Dusseault, GA-ASI, and Joseph Lyden, NSPA.Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capability. Additionally, MQ-9B's in-house-developed Detect and Avoid System aids its ability to fly in unsegregated airspace for domestic civilian operations, making it highly versatile for operations from Germany.In 2025, MQ-9B became the first large RPA to obtain a Military Type Certificate from the UK's Military Aviation Authority, certifying its safe operation without geographic restrictions, including over populous areas."We're thrilled that Germany has joined the list of NATO countries that have selected MQ-9B SeaGuardian," said GA-ASI CEO Linden Blue. "The proliferation of MQ-9B in Europe delivers commonality between NATO countries and for Germany, it will provide opportunities for interoperability with their fleet of P-8As."The acquisition negotiation was executed on behalf of Germany by NSPA, which has developed a contractual framework through the MQ-9 Support Partnership (MIC SP) for supporting cooperation amongst its member nations and enabling the procurement of MQ-9B for NATO Allies and Partners. NSPA has added MQ-9B to its portfolio of defense systems to contract on behalf of NATO nations, with the goal of enhancing interoperability for joint training and operations."This Support Partnership demonstrates how NSPA enables efficient, effective and responsive multinational acquisitions for advanced, interoperable capabilities. We are proud to support Germany in this strategic investment for maritime surveillance and security," said Ms. Stacy A. Cummings, NSPA General Manager.MQ-9B includes the SkyGuardian® and SeaGuardian® models as well as the Protector RG Mk1 that is currently being delivered to the United Kingdom's Royal Air Force (RAF). GA-ASI also has MQ-9B procurement contracts with Belgium, Canada, Denmark, India, Japan, Poland, Taiwan and the U.S. Air Force in support of the Special Operations Command and is looking forward to welcoming Germany to that group. MQ-9B has also been featured in various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, RIMPAC, and Group Sail.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact:GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

聖地亞哥, 2026年1月13日 - (亞太商訊 via SeaPRwire.com) - 德國聯邦國防軍裝備、資訊技術與現役支援局與北約支援與採購局（NSPA）宣布，將向通用原子航空系統公司（GA-ASI）採購八架MQ-9B海衛士®遙控飛行器（RPA）。該計畫包含四套可認證地面控制站，首架預計於2028年交付。德國加入日益擴大的北約國家行列，選用通用原子航空系統公司先進的MQ-9B RPA，看重其具備超長航程與續航力的多域作戰能力。該平台配備極地間衛星控制系統及除冰功能，可執行寒冷氣候任務。「海衛士」配備兩部多模式水面搜索雷達，可執行廣域海上監控任務，並可選配反潛作戰能力。此外，MQ-9B搭載自主研發的偵測與迴避系統，使其具備在非隔離空域執行國內民用任務的能力，使該機型在德國境內具備高度作戰靈活性。2025年，MQ-9B成為首款獲英國軍事航空管理局核發軍用型號認證的大型無人機，證實其具備無地域限制的安全運作能力，包括人口密集區域。通用原子航空系統公司執行長林登·布魯表示：「德國加入北約選用MQ-9B海衛士的行列，我們深感振奮。」 「MQ-9B在歐洲的普及將促進北約成員國間的共通性，對德國而言，更將創造與其P-8A機隊互通運作的契機。」此次採購談判由北約後勤支援夥伴關係（NSPA）代表德國執行。該機構透過「MQ-9支援夥伴關係」（MIC SP）建立合約框架，旨在促進成員國間合作，並協助北約盟國及夥伴採購MQ-9B。NSPA已將MQ-9B納入其為北約國家簽訂的防務系統組合，旨在提升聯合訓練與作戰的互操作性。NSPA總經理史黛西·A·卡明斯女士表示：「此支援夥伴關係彰顯NSPA如何推動高效、精準且具回應力的多國採購，以獲取先進互操作能力。我們榮幸支持德國這項海事監控與安全領域的戰略投資。」MQ-9B系列包含SkyGuardian®（天空守護者）與SeaGuardian®（海洋守護者）機型，以及目前正交付英國皇家空軍的Protector RG Mk1（守護者RG Mk1）。通用原子航空系統公司亦與比利時、加拿大、丹麥、印度、日本、波蘭、台灣及美國空軍簽訂MQ-9B採購合約，支援特種作戰司令部任務，並期待德國加入此行列。MQ-9B亦參與多項美國海軍演習，包括「北方邊緣」、「綜合戰鬥演習」、「環太平洋軍事演習」及「艦隊航行訓練」。關於通用原子航空系統公司通用原子航空系統公司是全球首屈一指的無人機系統製造商。掠食者®系列無人機系統累積飛行時數逾900萬小時，服役逾30年，包含MQ-9A死神®、MQ-1C灰鷹®、MQ-20復仇者®及MQ-9B天衛者®/海衛者®。本公司致力提供長航時、多任務解決方案，實現持續態勢感知與快速打擊能力。更多資訊請參閱：www.ga-asi.com Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian及SkyGuardian均為通用原子航空系統公司於美國及其他國家註冊之商標。聯絡方式：通用原子航空系統公司媒體關係部ASI-MediaRelations@ga-asi.com (858) 524-8101消息來源：通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TW, Jan 12, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC.Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market.TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreement. This international licensing collaboration reflects the potential value of products generated using OBI's Obrion™ ADC technologies.The licensed ADC candidate is derived from a high-affinity anti-glycan antibody provided by TegMine and was developed into an ADC by OBI using the Obrion™ ADC technology family, including the GlycOBI® glycan-conjugation technology, the dual-function enzymatic EndoSymeOBI®, and the highly hydrophilic linker HYPrOBI®. The ADC candidate generated with this proprietary site-specific glycan conjugation is homogeneous and scalable for manufacturing.Heidi Wang, Ph.D. Chief Executive Officer of OBI Pharma, said, "This strategic collaboration leverages the complementary strengths of both organizations. It not only supports the advancement of OBI's ADC product development but also expands opportunities for strategic partnerships using our innovative ADC technologies such as GlycOBI®. We look forward to working closely with TegMine to further develop this novel ADC that may benefit patients with urgent medical needs.""The transition from our successful Master Services Agreement to this global license agreement is a major milestone for TegMine," said Jeff Bernstein, Ph.D., Chief Executive Officer of TegMine Therapeutics. "By combining OBI's site-specific GlycOBI® conjugation with our proprietary antibodies discovered via the TegMiner™ platform, we have generated an ADC with exceptional tumor specificity. This TegMine program demonstrates the power of targeting cancer-specific glycan signatures to deliver potent payloads while sparing healthy tissue. We are excited to advance this program rapidly into the clinic."About GlycOBI®OBI has developed a unique glycan-based ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR). Powered by OBI's proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI's Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs with an efficient and scalable process under GMP conditions.During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI's linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies.About OBI PharmaOBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.OBI's research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel cysteine-conjugation technology ThiOBI®, to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2) and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). In addition to its ADC programs, OBI's assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.About TegMine TherapeuticsTegMine is redefining precision oncology by targeting highly expressed glycans and glycoproteins that drive cancer aggressiveness and immune evasion. Our mission is to eradicate cancer by identifying unique tumor antigens that are consistently prevalent across the tumor while being largely absent from healthy tissues. The company's proprietary TegMiner™ platform utilizes glyco-engineered cell lines and advanced mass spectrometry to identify previously inaccessible, cancer-specific glycan epitopes. This discovery engine is designed to generate high-specificity antibodies that deliver maximum therapeutic impact across numerous treatment modalities, including antibody-drug conjugates (ADCs) and other next-generation antibody formats. For more information, please visit www.tegminetx.com.Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Kevin Poulos, Chief Business OfficerOBI Pharma USA, Inc.+1 (619) 537 7698, ext. 102kpoulos@obipharma.comJeff Bernstein, Chief Executive OfficerTegMine Therapeutics, Inc.jeff@tegminetx.comSOURCE: OBI Pharma USA, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北，台灣, 2026年1月12日 - (亞太商訊 via SeaPRwire.com) - 台灣浩鼎生技（4174.TWO）宣布，已與 TegMine Therapeutics, Inc.（TegMine）簽訂商業授權合約，授權開發以醣為標靶的抗體藥物複合體（ADC）。TegMine 總部位於美國舊金山、專注於研發癌症相關抗醣或醣蛋白抗體的生技公司。依據合約條款，浩鼎將取得簽約金，並可於開發及商業化階段達成相關里程碑時, 獲得里程碑付款 。產品上市後，浩鼎亦將依年度淨銷售額按約定比例收取分潤權利金。基於保密條款，相關合約細節未予揭露；整體交易金額與近期市場上同類型授權交易大致相當。依授權合約，TegMine 將取得該 ADC 於全球開發與商業化權利。此國際授權合作展現利用浩鼎Obrion™ ADC 技術所開發之產品深具潛力。此次授權之 ADC 候選藥物源自 TegMine 所提供的高親和力以醣為標靶的單株抗體，由浩鼎運用 Obrion™ ADC 技術中的 GlycOBI® 醣偶聯技術、雙功能酵素 EndoSymeOBI® 與高親水性連接子 HYPrOBI® 進行開發， 採用專一性醣位點偶聯技術，打造具均質性並可大量生產  。浩鼎執行長王慧君博士表示：「這項策略性合作，充分發揮雙方技術優勢，不僅有助於推進浩鼎ADC產品開發，也積極拓展創新ADC技術平台如GlycOBI® 等策略性合作機會。浩鼎期待與 TegMine 共同開發創新的ADC，幫助具有迫切醫療需求的癌症病患。」TegMine Therapeutics執行長Jeff Bernstein 博士表示：「從成功的ADC研發服務合約（Master Services Agreement, MSA）到這次商業授權協議，對 TegMine 而言是一項重要里程碑。透過結合浩鼎的 GlycOBI® 專一性醣位點偶聯技術，以及 TegMine™ 平台所開發的專有抗體，我們已開發出具高度腫瘤專一性的 ADC。此計畫展現了以癌症特異性醣標靶的開發潛力，在保護正常細胞或組織的同時，有效地傳遞高活性藥物（payloads），實現精準治療。我們期待加速此計畫推進至臨床開發階段 。」關於 GlycOBI® 浩鼎所自主開發的醣類ADC關鍵技術平台GlycOBI®，採用「隨插即用」型式，可與任一抗體和藥物（payloads）兼容，並適用於多種藥物抗體比例（DAR）。在浩鼎專有的酵素技術（EndoSymeOBI®）和連接子技術（HYPrOBI®）搭配下，作為 Obrion™ ADC 技術家族核心組成之一的GlycOBI®，以高效率且可量產的GMP製程，製備具專一性位點與均質的 ADC。GlycOBI® 在偶聯過程中，可避免破壞抗體結構，並確保 ADC 與原始抗體具有相似的生物特性。此外，浩鼎的連接子技術可提升了藥物偶聯效率，並降低複合體聚集與降解風險，進一步優化ADC製程與品質穩定性。GlycOBI® 已成功克服傳統ADC技術限制，並在多項動物實驗中展現更優越的抗腫瘤活性與結構穩定性。關於浩鼎台灣浩鼎是產品已進展至臨床階段的全球癌症新藥開發公司， 於2002年成立，總部設於台灣。台灣浩鼎與子公司OBI Pharma USA, Inc.致力於開發抗癌新藥，希望幫助具有迫切醫療需求的癌症患者，提供新的治療選擇。台灣浩鼎的研發核心聚焦於新型抗體藥物複合體（Antibody-Drug Conjugates, ADC），透過專利的 Obrion™ 次世代藥物偶聯技術平台，建立了多元化ADC的藥物設計模式。此平台整合專有的酵素偶聯和連接子技術如GlycOBI®、GlycOBI DUO® 、EndoSymeOBI®、HYPrOBI® 與新型的半胱胺酸偶聯技術 ThiOBI® 推進次世代 ADC 開發解決方案。浩鼎已建立下一代 ADC 產品線，其中包含單抗 ADC：OBI-902（TROP2）、OBI-904（Nectin-4）；雙抗單藥 ADC：OBI-201 (HER2 x TROP2)；以及雙抗雙藥 ADC：OBI-221 (cMET x HER3)。此外，浩鼎的產品線亦包括全球首創 AKR1C3 靶向小分子前驅藥 OBI-3424，該藥物在腫瘤中高度表達的醛酮還原酶（AKR1C3）作用下，選擇性釋放強效 DNA 烷基化劑以治療癌症。更多資訊請參閱：www.obipharma.com。GlycOBI®、EndoSymeOBI®、ThiOBI®、HYPrOBI® 與 GlycOBI DUO® 為浩鼎的註冊商標。Obrion™ 為申請中之商標。關於 TegMine Therapeutics TegMine 以高度表現、驅動癌症侵襲性與免疫逃逸的醣與醣蛋白為研究重點，重新定義精準腫瘤治療。其使命在於根除癌症並用腫瘤組織中普遍且一致表現的獨特腫瘤抗原，但其多半不在人體健康組織中表現，以作為推動癌症治療發展的基礎。TegMine 專有的 TegMiner™ 平台結合醣工程化細胞株與先進質譜技術，用以辨識過去難以取得的癌症特異性醣表位。此技術的開發目的在產生具高度專一性的抗體，並可於多種藥物設計中發揮最大的治療潛力，包括抗體藥物複合體（ADCs）及其他次世代抗體。更多資訊請參閱：www.tegminetx.com。COMPANY CONTACT: Kevin Poulos, Chief Business Officer OBI Pharma USA, Inc. +1 (619) 537 7698, ext. 102 kpoulos@obipharma.com Jeff Bernstein, Chief Executive OfficerTegMine Therapeutics, Inc.jeff@tegminetx.com  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape ProductsIKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products.The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products.Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS).COSTA MESA, CA, Jan 12, 2026 - (ACN Newswire via SeaPRwire.com) - Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Company has signed a definitive licensing agreement with IKE Tech LLC ("IKE") to commercialize the first-ever AI-powered blockchain-based age-gating system for vape products in the United States.E-cigarettes and related vapor products are widely recognized as lower risk alternatives to combustible cigarettes. Accordingly, over the last 15 years, e-cigarette usage in the United States has grown significantly while combustible cigarette smoking rates have dropped. Public health advocates are pleased by this development.80-90% of adult consumers prefer flavored vapor productsBoth the e-cigarette industry and public health officials have come to recognize that 80-90% of adult consumers prefer flavored vapor products over tobacco, menthol, or "clear" flavors and understand that most adult cigarette smokers will continue using traditional combustible products if flavored vapor products are not available. However, operating on the assumption that flavored vapor products can be highly attractive to youth - and that the priority for public health must be the prevention of nicotine usage by underage consumers - to date, the FDA has not authorized for sale in the United States a single flavored vapor product.California, Massachusetts, parts of New York State, and many other regions across the country have also imposed significant restrictions or outright bans on flavored ENDS products. These bans have led to an explosion of illicit foreign products, confusion among retailers, and, most unfortunately, to the elimination of legal flavored products as an option for many adult cigarette smokers who would prefer to switch to far less harmful (flavored) vapes.In this environment, it is apparent that the only way to provide adult smokers with the flavored vapor products that they desire over far more harmful combustible cigarettes, is to "age-gate" flavored vapor products in such a way as to eliminate the possibility that underage consumers can activate or utilize the devices.Numerous companies in the vapor products industry have spent years and millions of dollars on the development of age-gating systems. Most of these systems, however, do not feature "continuous age-gating" (and may, therefore, result in a scenario where the ineffectively age-gated product is purchased by an adult consumer and subsequently used by an underage individual), or the age-gating mechanism is so complex and cumbersome that it renders the device commercially infeasible. Further, to date, no age-gated vapor product has received FDA authorization to be sold in the US market.Continuous age-gating is the only effective means of preventing youth usageCharlie's age-gated SBX Disposable vape - utilizing IKE's patented technology - prevents underage consumers from activating or utilizing the device using BLE-enabled chips and biometric authentication to control the device continuously and in real-time.In a multi-center Human Factors Validation Study designed to evaluate (i) effectiveness in preventing underage access to the ENDS products, (ii) usability, and (iii) safety, results showed:100% of users successfully completed age verification0% of underage users were able to activate a device100% of devices deactivated after a period of inactivity or loss of Bluetooth signal91% rated the app "Extremely Easy" or "Very Easy" to useErrors occurred in only 1% of task attemptsThe results of the Human Factors Validation Study confirm that the IKE age-gating system effectively prevents underage access and provides a highly user-friendly experience for adults. Full findings from the study will be published on clinicaltrials.gov, and the Abstract can be found on https://www.iketech.com/clinical-trials/protocolsCharlie's will test market the IKE age-gating system this spring with a special line of the Company's popular SBX nicotine analogue product; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS)."There is a large un-met need for technologies that can satisfy or accommodate concerns the FDA has related to youth access... which means there is a multi-BILLION market opportunity for flavored vapes that are inoperable for underage individuals," explained Henry Sicignano, Charlie's President. "We believe Charlie's could become the first Company to demonstrate to the FDA that age-gated flavored vape products are indeed ‘appropriate for the protection of public health.' Such a success would not only be game changing for Charlie's, but also transformational for the entire industry."John Patterson, President of IKE Tech explained, "IKE is establishing the blueprint for responsible vaping globally. Our agreement with Charlie's represents an industry first in deploying proprietary technologies that protect public health, enable regulatory compliance, and drive sustainable industry growth. We chose to partner with Charlie's because Charlie's non-nicotine SBX product line enables immediate deployment of age-gated technology to the US market, ahead of standard PMTA timelines. This partnership is proof that the industry can bring manufacturers, regulators, and innovators together to protect youth, secure the supply chain, and ensure responsible access for adults.""We believe age-gating is both a responsible business practice as well as a significant competitive advantage for Charlie's," commented Ryan Stump, Charlie's Chief Operating Officer. "By voluntarily age-gating a product that does not require FDA approval, Charlie's will demonstrate to public health officials - and to compliance-minded national convenience store chains - that the Company is absolutely committed to regulatory compliance and youth access prevention."About Charlie's Holdings, Inc.Charlie's Holdings, Inc. (OTCQB:CHUC) is an industry leader in the premium vapor products space. The Company's products are sold around the world to select distributors, specialty retailers, and third-party online resellers through subsidiary company Charlie's Chalk Dust, LLC has developed an extensive portfolio of brand styles, flavor profiles, and innovative product formats.For additional information, please visit Charlie's corporate website at: Chuc.com and the Company's branded online websites: sbxvape.com, CharliesChalkDust.com, enjoypachamama.com, and Pacha.co.About IKE Tech LLCIKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. IKE is dedicated to advancing next-generation Identity and Age Verification (IAV) systems for ENDS devices. Its patented BLE System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices -ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication.Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, existing and anticipated markets and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms, and similar expressions, are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ongoing ability to quote its shares on the OTCQB; whether the Company will meet the requirements to up-list to a national securities exchange in the future; the Company's ability to successfully increase sales and enter new markets; whether the Company's PMTA's for its nicotine-containing products will be authorized by the FDA, and the FDA's decisions with respect to the Company's future PMTA's for nicotine products; the Company's ability to manufacture and produce products for its customers; the Company's ability to formulate new products; the acceptance of existing and future products; the complexity, expense and time associated with compliance with government rules and regulations affecting nicotine, synthetic nicotine, products containing nicotine substitutes, and products containing cannabidiol; litigation risks from the use of the Company's products; risks of government regulations; the impact of competitive products; and the Company's ability to maintain and enhance its brands, as well as other risk factors included in the Company's most recent quarterly report on Form 10-Q, annual report on Form 10-K, and other SEC filings. These forward-looking statements are made as of the date of this press release and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.Investors Contact:IR@charliesholdings.comPhone: 949-570-0691SOURCE: Charlie's Holdings, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IKE專利生物識別BLE藍牙晶片與區塊鏈應用程式，將確保未成年人無法啟動或使用查理斯控股的年齡驗證產品。IKE授權協議賦予查理斯控股在青少年防癮領域（FDA首要監管重點）的先發優勢，並享有三年獨家銷售權，適用於年齡驗證型尼古丁替代產品。查理公司將於今春以旗下熱門的SBX尼古丁類比產品線測試IKE年齡驗證系統；同時計劃將此革命性技術整合至其PACHA品牌電子尼古丁傳遞系統（ENDS）。加州科斯塔梅薩, 2026年1月12日 - (亞太商訊 via SeaPRwire.com) - 高端蒸汽產品領域的行業領導者查理控股公司（Charlie's Holdings, Inc.）（OTCQB：CHUC）（下稱「查理控股」或「本公司」）今日宣布，已與IKE Tech LLC（下稱「IKE」）簽署最終授權協議，將在美國商業化首個基於人工智慧的區塊鏈年齡驗證系統，用於蒸汽產品的年齡限制管理。電子煙及相關霧化產品被廣泛認可為比燃燒式香菸風險更低的替代品。據此，過去十五年間美國電子煙使用率顯著增長，而燃燒式香菸吸食率則持續下降。公共衛生倡導者對此發展深表欣慰。80-90%的成年消費者偏好調味型霧化產品。電子煙產業與公共衛生官員均已認知到，80-90%的成年消費者偏好調味煙油產品而非菸草、薄荷或「原味」煙油，並理解若無調味煙油產品可供選擇，多數成年吸菸者將持續使用傳統燃燒型產品。然而基於「調味霧化產品可能高度吸引青少年」的假設——且公共衛生首要任務應是防止未成年人接觸尼古丁——迄今美國食品藥物管理局（FDA）尚未核准任何調味霧化產品在美國銷售。加州、麻州、紐約州部分地區及全美眾多區域亦對調味電子煙產品實施嚴格限制甚至全面禁令。此類禁令導致非法進口產品激增、零售商陷入混亂，最不幸的是，許多本可轉用危害程度低得多的調味電子煙產品的成年吸菸者，如今喪失了合法調味產品的選擇權。在此環境下，顯而易見的解決之道是：唯有透過「年齡驗證機制」管控調味電子煙產品，徹底杜絕未成年消費者啟動或使用裝置的可能性，方能讓成年吸菸者獲得他們渴望的調味霧化產品，從而取代危害性遠高於電子煙的傳統燃燒式香菸。眾多霧化產品企業已投入數年心力與數百萬美元研發年齡驗證系統。然而多數系統未具備「持續年齡驗證」功能（可能導致成年消費者購買後，產品被未成年人使用），或因驗證機制過於複雜繁瑣而使裝置失去商業可行性。此外，迄今為止，尚未有任何實施年齡驗證的電子煙產品獲得美國食品藥物管理局（FDA）授權於美國市場銷售。持續年齡驗證是防止青少年使用的唯一有效手段查理的年齡驗證型SBX一次性電子煙——採用IKE專利技術——透過藍牙低功耗晶片與生物特徵驗證，持續即時控制裝置，防止未成年消費者啟動或使用本產品。在多中心人體工學驗證研究中，針對以下三項指標進行評估：(i) 防止未成年人接觸電子煙產品之有效性、(ii) 使用便利性、(iii) 安全性，結果顯示：• 100% 使用者成功完成年齡驗證• 0% 未成年使用者能成功啟用裝置• 100% 裝置在閒置一段時間或失去藍牙訊號後自動停用• 91% 使用者評定應用程式「極易」或「非常易」於操作• 僅 1% 的任務嘗試出現錯誤人類因素驗證研究結果證實，IKE年齡驗證系統能有效防止未成年人接觸，同時為成年使用者提供高度友善的操作體驗。完整研究報告將發布於clinicaltrials.gov網站，摘要可於https://www.iketech.com/clinical-trials/protocols查閱。查理公司將於今春透過旗下熱門產品SBX尼古丁類比品的特別系列，對IKE年齡驗證系統進行市場測試；同時，查理公司計劃將這項革命性技術整合至其PACHA品牌的電子尼古丁傳遞系統（ENDS）。查理公司總裁亨利·西奇尼亞諾解釋：「市場亟需能滿足FDA對青少年接觸電子煙顧慮的技術解決方案...這意味著針對未成年人無法使用的調味電子煙，存在數十億美元的市場商機。」 「我們相信查理公司有望成為首家向FDA證明『年齡門檻調味電子煙產品確實符合公共衛生保護標準』的企業。此項突破不僅將改變查理公司的命運，更將重塑整個產業格局。」IKE科技總裁約翰·帕特森闡述：「IKE正為全球建立負責任的電子煙藍圖。我們與查理公司的協議開創業界先河，透過專利技術實現三重目標：保障公共健康、確保法規合規、推動產業永續發展。選擇與查理斯合作，是因為其無尼古丁SBX產品線能讓年齡門檻技術跳過標準PMTA審核時程，立即部署至美國市場。此合作證明產業可凝聚製造商、監管機構與創新者，共同守護青少年、保障供應鏈安全，並確保成年人負責任地使用產品。」查理公司營運長萊恩·斯通普表示：「年齡驗證機制既是負責任的商業實踐，亦為查理公司創造顯著競爭優勢。透過主動為無需FDA核准的產品實施年齡驗證，查理公司將向公共衛生官員及注重合規的全國性便利店連鎖企業證明，本公司對法規遵循與青少年防堵措施的絕對承諾。」關於查理控股公司查理控股公司（OTCQB：CHUC）是高端蒸汽產品領域的行業領導者。公司透過子公司查理粉筆灰有限責任公司（Charlie's Chalk Dust, LLC），向全球精選經銷商、專業零售商及第三方線上轉售商銷售產品，已開發出涵蓋多元品牌風格、風味組合及創新產品形式的完整產品組合。欲了解更多資訊，請造訪查理企業官網：Chuc.com，以及旗下品牌網站：sbxvape.com、CharliesChalkDust.com、enjoypachamama.com 及 Pacha.co。關於 IKE Tech 有限責任公司IKE Tech 有限責任公司是由 Ispire Technology Inc.、Touch Point Worldwide Inc.（以 Berify 名義經營）及 Chemular Inc. 共同組成的合資企業。IKE 致力於為電子煙裝置開發新一代身分與年齡驗證（IAV）系統。其專利藍牙低功耗系統單晶片技術，使製造商能將可客製化且互通的存取控制系統嵌入電子煙裝置，透過即時行動裝置與生物特徵驗證機制，確保僅授權成人使用並防止未成年人接觸。安全港聲明本新聞稿包含《1995年私人證券訴訟改革法案》安全港條款所界定之「前瞻性陳述」，包括但不限於關於本公司整體業務、現有及預期市場，以及未來銷售與支出預期的聲明。諸如「預期」、「預估」、「應」、「相信」、「目標」、「 「規劃」、「目標」、「估計」、「潛力」、「預測」、「可能」、「將」、「可能」、「應」、「意圖」等詞彙及其變體或否定形式，以及類似表述，皆旨在識別此類前瞻性陳述。前瞻性陳述受多種風險與不確定性影響，其中多數涉及超出本公司控制範圍的因素或情況。基於下列因素（包括但不限於），本公司實際成果可能與前瞻性陳述所載或暗示內容存在重大差異：本公司能否持續於OTCQB市場掛牌交易；未來是否符合升級至全國性證券交易所的上市要求； 公司能否成功提升銷售額並開拓新市場；公司含尼古丁產品的PMTA申請能否獲FDA核准，以及FDA對公司未來尼古丁產品PMTA申請的裁決；公司為客戶製造生產產品的能力；公司開發新產品的能力；現有及未來產品的市場接受度； 遵守影響尼古丁、合成尼古丁、含尼古丁替代品產品及含大麻二酚產品之政府法規所涉及的複雜性、成本與時間； 因使用本公司產品引發的訴訟風險；政府監管風險；競爭產品的影響；以及本公司維持與提升品牌的能力，此外還包括本公司最新季度報告（10-Q表）、年度報告（10-K表）及其他美國證券交易委員會（SEC）申報文件所載之其他風險因素。本新聞稿所載前瞻性陳述係基於管理層當前預期、估計、預測及假設，並以發布當日資訊為準。除法律要求外，本公司無義務因新資訊、未來事件或預期變動而更新本新聞稿所含任何前瞻性陳述。投資者聯絡窗口：IR@charliesholdings.com 電話：949-570-0691消息來源：Charlie's Holdings, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 12, 2026 - (ACN Newswire via SeaPRwire.com) – Kicking off a brand-new year, the 52nd HKTDC Hong Kong Toys & Games Fair, 17th HKTDC Hong Kong Baby Products Fair and 24th Hong Kong International Stationery & School Supplies Fair, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd, opened today at the Hong Kong Convention and Exhibition Centre, running over four consecutive days. Highly international in scope, the three fairs are bringing together exhibitors and buyers from around the world, creating networking and business opportunities and helping to foster cross-regional trade cooperation.The Joint Opening Ceremony for the Toys & Games Fair and Baby Products Fair was held this morning, officiated by Hong Kong Special Administrative Region (HKSAR) Government Under Secretary for Commerce and Economic Development Dr Bernard Chan, HKTDC Executive Director Sophia Chong and HKTDC Toys Advisory Committee Chairman Bryant Chan.Jenny Koo, HKTDC Deputy Executive Director, said: “The three fairs, themed ‘New Play for All’, cover three key areas: play, growth and creativity. As Asia’s flagship trade event of its kind, the Toys & Games Fair is tapping into the immense potential of the pop toy and collectibles market. This year, we have launched the new ‘Pop & Play’ pavilion. Open to both trade buyers and the public, the pavilion offers enhanced cross-sector business opportunities, facilitating collaboration and enabling interaction with fans and collectors of designer toys."Ms Koo added: “The three fairs have attracted more than 2,600 exhibitors from 37 countries and regions, including new participants from Bangladesh, New Zealand and Norway, alongside returning exhibitors from Hong Kong, the Chinese Mainland, Asia-Pacific including ASEAN, the Middle East, South Africa, Europe and the United States, presenting a truly international lineup. The HKTDC has organised over 200 buyer missions from more than 40 countries and regions to attend and source products at the fairs. In addition to traditional distributors and importers, we have also invited major e-commerce platforms, importers, department stores, specialty retailers, retail chains and sourcing offices, creating new cross-regional and cross-sector opportunities for the industry."Three fairs reveal multiple product trendsSeveral product trends are emerging from this year's exhibitors, pointing the way forward for the industry to gain a first-mover advantage. These trends include:Pop culture and collectibles toys: The “kidult” and toy collecting markets continue to grow in popularity, injecting strong growth momentum into the toy industry. The “Pop & Play” pavilion brings together some 150 famous local and international IPs – including top names such as B.Duck, CardFun, CR7® LIFE, Hot Toys, LAURA, Moshow Toys, Play Bonito®, Room One, threezero, TUTU MOKEY and more. Some IPs will launch fair premieres and global limited-edition collectibles, including MOMOLAND's debut dolls (Booth: CH-F16); TUTU MOKEY collectible figurines and art sculptures limited to 100 and 88 pieces globally (Booth: CH-F05); CM Concepts Limited's Mazinger Z Playing Cards, limited to 1,500 sets worldwide (Booth: CH-G06); and Dongguan Manbo Brand Management Co., Ltd's Father Joka doll, limited to 100 pieces (Booth: CH-A16).In addition, the Kidult World in Hall 3E will showcase toys catering to adults, including the popular NARUTO Collectible Metal Keychain (Booth: 3E-E13); the officially licensed Transformers Generation One: AMK MINI Series Model Kit (WAVE 3) (Booth: 3E-C02); and a premium jigsaw puzzle from Poland (Booth: 3E-C13).Happy Ageing products in demand: With ageing populations becoming a global reality, toys and games designed specifically for seniors or intergenerational family fun have become a rapidly growing product category. The new Happy Ageing label is being introduced at this year’s Toys & Games Fair to help buyers identify toys and related products for seniors. More than 40 exhibitors will adopt the label and showcase relevant products, including colour-sorting exercises designed by a Hong Kong exhibitor that train muscles in the thumb, index and middle fingers using clips (Booth: 1CON-015); a companion plush toy that alleviates loneliness and soothes emotions for seniors (Booth: 1D-C38); and the DIY Flip Monster from Taiwan (Booth: 1D-C13).Sustainable products stimulate demand: In recent years, more parents have opted for eco-friendly toys to reduce their environmental impact, reflecting the trend for sustainable consumption. In addition to the Green Toys zone at the Toys & Games Fair, both the toys and stationery events employ the Green Solutions label for identification, with more than 400 exhibitors displaying the green leaf logo this year – an increase of approximately 10% compared to 2025.In the Green Toys zone, one exhibitor presents the Beach Life OBP Material Beach Funnel Set crafted from ocean bound plastic (OBP), transforming plastic waste that might otherwise pollute the oceans into delightful and engaging toys, while simultaneously sparking children's boundless creativity and hands-on skills on the beach (Booth: 1C-D02). At the Baby Products Fair, an exhibitor is showcasing baby push walker toys, certified under the FSC and Global Recycling Standard (GRS) and reflecting eco-friendly, sustainable and responsible production practices aligned with forest conservation goals (Booth: 3F-G26).Learning and play combined: Many parents favour products that enhance their children's cognitive, social, intellectual and aesthetic development, enabling learning through play. This trend has driven demand for educational and intellectually stimulating products. At the Toys & Games Fair, a Hong Kong exhibitor is showcasing Canadarm toys (Booth: 1E-C35) that allow children to assemble and operate robotic arms, fostering an interest in machinery while developing grip strength and hand-eye coordination. Another exhibitor is presenting its 2-in-1 Digital Microscope & Telescope, integrating STEM (science, technology, engineering and mathematics) natural sciences into toys (Booth: 1E-A02).Korean film/TV-related products become a new focus: Blending music, action and fashion, the popular animated film KPop Demon Hunters has garnered significant attention. The character Derpy is particularly well-known, with its squishy catering to the growing fanbase for KPop characters (Booth: 1E-B16). The exhibitor also features a replica of the Gonggi Tossing Game featured in Season 2 of Squid Game, bringing to life one of Korea's most iconic childhood games while allowing fans to relive the thrill of the series.Pinkfong, the Korean brand beloved by children for its Baby Shark videos and toys,    makes its debut appearance with the Pinkfong Baby Shark Alphabet Learning Bus, a best-selling early-learning toy that helps preschoolers explore letters and vocabulary (Booth: 1CON-044).Interactive activities and IP development opportunities at “Pop & Play”The inaugural “Pop & Play” pavilion not only showcases trendy toys from around 150 popular IPs but also features a series of interactive elements – including photo opportunities, creative exchanges and autograph sessions – allowing buyers and the public to fully experience the pop toy culture. Activities commenced today with artist Joey Thye sharing her journey from an IP enthusiast and investor to an IP creator during the “IP Walkthrough with Joey Thye” event. Renowned artists and designers will share their creative insights and artistic visions through seminars and autograph sessions, including b.wing, founder of la b.wing Galerie Ltd; Kenny Wong, creator of the iconic Molly and founder of Brothersfree; Steven Choi, founder of Zu and Pi; and Winson Ma, founder and creative director of Winson Classic Creation. On 14 January (Wednesday), in the key thematic seminar titled “Explosive Growth of IP Economy: from Local Success to Global Reach”, Maxim Wang, Head of Toys Category, Alibaba 1688 and Leung Man Lai Lily, CEO and Co-Founder, Nikopicto Limited, will delve into the enormous business opportunities and future trends presented by the collectible toy industry.Mascots Ah Pop and Ah Play will make appearances in the “Pop & Play” pavilion for interactive photo opportunities with visitors. In addition, Hot Toys will showcase eye-catching giant statues including Marvel's Iron Man, Disney's Stitch and Star Wars' Grogu COSBI. threezero will display the giant statue of ROBO-DOU Evangelion 13 from “Evangelion: New Theatrical Edition”, while Asia Partners will exhibit a rare Cristiano Ronaldo autographed jersey and Semk Global Marketing Limited will present its inflatable and fibreglass B.Duck installations.This year’s Toys & Games Fair continues to feature group pavilions from the Chinese Mainland, Taiwan and Korea, as well as the World of Toys Pavilion, featuring selected European exhibitors. The popular Smart-Tech Toys and Games from last year will present toys with smart and AI functions, such as a smart remote-controlled transforming ball operated via smartphone (Booth: 1C-F02) and artificial intelligence (AI) cat dolls (Booth: 1D-A36).Two zones expand at the Baby Products FairAt the Baby Products Fair, the World of Strollers and Gear and ODM Strollers and Gear zones are together hosting approximately 230 exhibitors, with an increase in both exhibitor numbers and fair area compared to last year. The Selection of Europe Pavilion is returning in 2026 together with the Korean and Hong Kong Children, Babies, Maternity Industries Association pavilions.Both the Toys & Games Fair and Baby Products Fair continue to feature the popular Brand Name Gallery, bringing together over 380 well-known brands from around the globe and allowing buyers to source the latest designs and high-quality products from a variety of manufacturers. These include educational toys from Eastcolight at the Toys Fair (Booth: 1E-A02), the Fetchin' Fun Pet Splash Pad (Booth: 1D-B02) and the Claw Crane based on the classic Pac-Man game (Booth: 1E-B20). Meanwhile, the Baby Products Fair features items such as a minimalist, safe pushchair with freely combinable accessories (Booth: 3G-A03).Stationery & School Supplies Fair welcomes New Zealand exhibitor for the first timeJointly organised by the HKTDC and Messe Frankfurt (HK) Ltd, the Hong Kong International Stationery & School Supplies Fair welcomes exhibitors from New Zealand for the first time, showcasing a range of optical magnifiers.  The fair features numerous premium stationery brands, including AP, ChungHwa, Marshmallow, Mirage, Sayyed, SUPERDOTS, TATOU and Toursun offering buyers the latest creative art supplies and stationery gifts.Asia Toys & Games Forum opens tomorrow, revealing global strategic developmentThemed “Empowering the Toy Industry for Global Success”, this year’s Asia Toys & Games Forum has invited international experts to discuss the latest industry updates and developments. It will include sharing on the toys and games market outlook and opportunities by Loo Wee Teck, Global Insights Manager, Toys and Games, Euromonitor International; global IP ecosystem and merchandise strategies by Alex Lin, Vice President and General Manager, Disney Consumer Products, Greater China and Korea, The Walt Disney Company; unlocking product certification for global market access by Phoebe Lee, Global Head – Toys & Juvenile Products, SGS Hong Kong Limited; and exploring the design and business landscape of the seniors toy market in Asia by Yukai Engineering Inc., recipient of multiple international product design awards, and Ageing Asia. Other seminars will cover important topics such as toy safety regulations and regulatory developments, marketing strategies incorporating AI and robotics, and trends in modern childcare and infant products.The three exhibitions offer buyers a unique one-stop sourcing solution, creating more cross-industry business opportunities. Under the EXHIBITION+ model, the fairs combine access to the physical exhibition with the Click2Match smart-matching platform, which enables online business meetings. The online exhibition will be accessible from 5 to 22 January 2026, helping to create more business opportunities for participating companies. Buyers can also scan QR codes at exhibitor booths and display showcases using the Scan2Match function to bookmark their favourite exhibitors, browse product information and engage with exhibitors during and after the fair, helping to build more business connections.Photo download: https://bit.ly/49yRDV6The Hong Kong Toys & Games Fair, Hong Kong Baby Products Fair and Hong Kong International Stationery & School Supplies Fair opened today. The four-day fairs run concurrently from 12 to 15 January at the Hong Kong Convention and Exhibition Centre, bringing together more than 2,600 global exhibitors from 37 countries and regions. The events showcase a high level of internationalisation and help to foster cross-regional business cooperationOfficiating at today’s Joint Opening Ceremony for the Toys & Games Fair and Baby Products Fair are HKTDC Toys Advisory Committee Chairman Bryant Chan (second left), Hong Kong SAR Government Under Secretary for Commerce and Economic Development Dr Bernard Chan (centre), and HKTDC Executive Director Sophia Chong (second right)The “Pop & Play” pavilion debuts at this year’s Toys & Games Fair, featuring around 150 popular international and local IPs. The pavilion is open to industry participants and the wider toy-loving public, providing an ideal platform for business collaboration while fostering interaction between the industry, toy collectors and fansHKSAR Government Under Secretary for Commerce and Economic Development Dr Bernard Chan visited exhibits at the “Pop & Play” pavilion, including a Cristiano Ronaldo autographed jerseyMascots Ah Pop and Ah Play made appearances in the “Pop & Play” pavilion, providing interactive photo opportunities with visitorsThe “Pop & Play” pavilion features multiple photo opportunities, including eye-catching giant statues of Marvel's Iron Man, Disney's Stitch and Star Wars' Grogu COSBI from Hot Toys, a giant statue of ROBO-DOU Evangelion 13 from “Evangelion: New Theatrical Edition”, a rare Cristiano Ronaldo autographed jersey and inflatable and fibreglass B.Duck installationsThis year’s Toys & Games Fair has an impressive pavilion lineup to promote creative products to international buyers, with exhibitors from Hong Kong, the Chinese Mainland, Taiwan and Korea, as well as the World of Toys Pavilion featuring selected European exhibitorsThe Toys & Games and Baby Products Fairs continue to feature the popular Brand Name Gallery, bringing together over 380 well-known brands from around the globeAt the Baby Products Fair, the World of Strollers and Gear and ODM Strollers and Gear zones are together hosting approximately 230 exhibitors, with an increase in both exhibitor numbers and fair area compared to last yearThe Hong Kong International Stationery & School Supplies Fair showcases a range of distinctive productsFair websitesHKTDC Hong Kong Toys & Games Fair: hktoyfair.hktdc.comHKTDC Hong Kong Baby Products Fair: hkbabyfair.hktdc.comHong Kong International Stationery & School Supplies Fair: hkstationeryfair.comRegister for free Pop & Play ticket: https://www.hktdc.com/event/hktoyfair/en/pop-playMedia enquiriesHKTDC’s Communications & Public Affairs Department:Katy WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgWinnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月12日 - (亞太商訊 via SeaPRwire.com) - 1月8日，聯想控股旗下聯想之星與君聯資本所投手術機器人領軍企業精鋒醫療（02675.HK）成功登陸港交所，發行價為每股43.24港元，股票代碼：2675.HK。這家公司上市首日開盤漲超38%，市值達到230億港元。精鋒醫療成立於2017年，是中國領先的手術機器人公司，是中國首家、全球第二家同時取得多孔腔鏡手術機器人、單孔腔鏡手術機器人及自然腔道手術機器人註冊審批的公司。公司專注於手術機器人及配套器械的研發、生產與銷售，產品覆蓋泌尿外科、婦科、普外科、胸外科等多科室微創手術需求。精鋒醫療亦是國家高新技術企業、國家專精特新"小巨人"企業，曾獲2023年度國家科學技術進步獎二等獎。公司在全球共擁有700多項專利及專利申請，其中核心產品超過400項專利，創新突破打破了我國手術機器人領域進口技術的長期壟斷。作為一家醫療器械行業的先進手術機器人公司，精鋒醫療擁有多孔腔鏡手術機器人和單孔腔鏡手術機器人。弗若斯特沙利文資料顯示，2024年精鋒醫療在中國售出20台多孔腔鏡手術機器人，在國內製造商中銷量排名第一。截至2025年6月30日，公司核心產品全球銷售合約量已達61台，並已完成超過14,000例機器人輔助臨床手術，產品性能與可靠性得到市場驗證。2025年10月，精鋒醫療自主研發的精鋒單孔腔鏡手術機器人SP1000及單多孔手術機器人超級系統MSP2000正式獲得歐盟CE認證（MDR）。這標誌著全球首個"單多孔一體化"手術機器人平台成功進入國際市場，開啟了由中國智慧定義的"全能微創"手術新時代。聯想之星：連續出手兩次，唯一一家系統佈局醫療健康的早期投資機構一路走來，這家由天津大學校友王建辰和高元倩創立的公司得到了聯想之星、聯想控股、君聯資本、紅杉中國、博裕投資等眾多知名投資者的支持。其中，聯控旗下聯想之星是股東裡面唯一一家系統佈局醫療健康領域的早期投資機構。按照230億港元市值粗略計算，兩筆投資已經讓聯想之星獲得了近20倍的賬面回報。"精鋒醫療成功上市，也使得聯想之星在人工智能、機器人領域得到進一步深化。"聯想之星總裁、主管合伙人王明耀表示，"人工智能、機器人將持續改造各行各業，手術機器人是其中一個非常好的品類，會發揮越來越大的作用。"在2018年與精鋒醫療初次接觸，聯想之星團隊便發現對方在眾多方面表現驚艷，但嚴謹的他們選擇進一步調研，迅速啟動了對手術機器人賽道的橫向掃描與深度研究。通過走訪大量醫院與專家訪談，以及與業內人士交流，最終構成了他們重注前的信心與基礎。感受到這家公司蘊含的發展潛力後，聯想之星果斷做出投資的決定，並對其追加投資。此後，借助聯想之星的投後幫助和創業CEO特訓班等資源，精鋒醫療的發展得到進一步提速。事實上，在當時果斷並堅定地投手術機器人，需要莫大的勇氣和決心。能做出如此前瞻性的快速決策，源於聯想之星自上而下的打法，先做深入分析，然後再尋找項目。這樣的打法，也有賴於此前多年的認知、資源、經驗的積累。早在2010年，聯想之星便開始關注人工智能的底層技術。到了2015年，聯想之星明確了人工智能、機器人會持續改造各行各業，並獨立成立了投資小組，當時在硅谷的團隊也在該賽道投了幾十個項目。正是基於長期且深刻的認知，聯想之星在2020年拿出當時一次能給到單個項目的最大金額，並且在下一輪追加投資精鋒醫療，成為精鋒醫療股東里唯一一家系統性佈局醫療健康領域的早期投資機構。驕人成績的取得，也源於聯想之星在醫療健康領域的多年深耕。早在2010年，聯想之星便將醫療健康作為重點投資佈局的領域之一，成為最早系統佈局醫療健康領域的早期投資機構之一。隨著優秀的項目越投越多，這家投資機構在醫療健康領域形成了"生物醫藥"與"數智醫療"兩大板塊。在聯想之星的佈局中，生物醫藥包括創新藥、基因技術與服務、診斷與高值耗材等；數智醫療則是利用人工智能、大數據、機器人等技術，對藥物研發、醫療器械、醫療服務、保險支付與健康管理等各方面進行升級賦能的機會。隨著科創賽道競爭白熱化，聯想之星表示將選擇堅持投更"新"投更"精"。"投更新，是要在行業明確的趨勢和拐點到來之前，提前進行預判；投更精，是要在估值上漲的前提下，優中選優。"在王明耀看來，人工智能、機器人、大數據等最新技術與整個醫療產業的結合，實際上蘊含著非常大的機會，"基於聯想之星的能力和經驗積累，我們未來在醫療健康領域會繼續加大投入。"君聯資本：與社保基金中關村自主創新專項基金首次迎來投資企業上市聯想控股旗下君聯資本與社保基金中關村自主創新專項基金（以下簡稱"社保中關村專項基金"）亦在2024年、2025年三次投資精鋒醫療。投資後，君聯資本充分發揮在醫療科技領域的深厚產業資源與投後服務能力，在公司戰略規劃、高端人才引進、全球市場拓展等方面提供了支持，助力公司鞏固技術壁壘並加速產品商業化落地。作為中關村"先行先試"改革之一，社保中關村專項基金首次迎來投資企業上市，這一里程碑事件不僅彰顯了君聯資本在硬科技領域的敏銳洞察力和投資能力，更凸顯了長期耐心資本在支持科技創新方面邁出的重要一步。君聯資本表示：精鋒醫療的成功上市，是其以原創技術突破國際壟斷，引領中國手術機器人產業發展的標誌性成果。公司憑借全面的產品佈局、經臨床驗證的卓越性能以及快速商業化的能力，不僅在國內市場迅速確立領導地位，更在國際舞台上展現出強大競爭力。期待公司以上市為新起點，持續加大研發創新與生產投入，進一步拓展臨床應用與全球市場，賦能全球外科醫生與患者，為推動中國高端醫療裝備的自主可控與產業升級做出更大貢獻。長期以來，君聯資本在醫療健康領域進行系統性佈局，重點關注生物技術、創新藥、醫療器械及AI+醫療等前沿方向。在高端醫療器械與醫療機器人賽道，君聯資本表示，將持續看好具備底層技術創新和全球商業化能力的優秀企業。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com